Literature DB >> 8102642

3,4-Methylenedioxymethamphetamine, serotonin and memory.

G A Ricaurte1, A L Markowska, G L Wenk, G Hatzidimitriou, J Wlos, D S Olton.   

Abstract

The recreational drug (+/-)-3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") is toxic to central serotonin (5-HT) neurons, but few long-term functional consequences of MDMA neurotoxicity have been identified. Because 5-HT has been implicated in learning and memory, the present study was undertaken to examine whether MDMA, by damaging 5-HT neurons, altered mnemonic function on a long-term basis. Rats were treated with saline, MDMA or 5,7-dihydroxytryptamine/desmethylimipramine. The latter treatment group was included to assess the effects of larger 5-HT neuronal lesions than are possible with MDMA. Four weeks after drug treatment, memory was assessed in three different variations of spatial alternation in a T-maze: acquisition with a constant and short delay interval, performance with variable delays and treatment with scopolamine. Upon completion of the behavioral studies, the neurotoxic effects of the drugs were assessed chemically and anatomically. MDMA, which produced a substantial and selective reduction of brain 5-HT, had no effect on choice accuracy. 5,7-dihydroxytryptamine/desmethylimipramine which produced a near-total reduction of 5-HT and a modest reduction of norepinephrine, impaired choice accuracy in all three variations of the task. These data suggest that selective damage to the 5-HT system, like that produced by MDMA, is not sufficient to impair memory, but that combined damage to the 5-HT and norepinephrine systems can disrupt performance in tasks that require recent memory. Because Alzheimer's disease involves impairments in acetylcholine, 5-HT and norepinephrine systems, animals with combined lesions may provide a useful model to study the mnemonic dysfunctions characteristic of this disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8102642

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Does recreational ecstasy use cause long-term cognitive problems?

Authors:  P A Kelly
Journal:  West J Med       Date:  2000-08

2.  Effects of MDMA exposure on the conditioned place preference produced by other drugs of abuse.

Authors:  J C Cole; H R Sumnall; E O'Shea; C A Marsden
Journal:  Psychopharmacology (Berl)       Date:  2003-02-25       Impact factor: 4.530

Review 3.  A developmental comparison of the neurobehavioral effects of ecstasy (MDMA).

Authors:  Brian J Piper
Journal:  Neurotoxicol Teratol       Date:  2006-10-20       Impact factor: 3.763

4.  Impaired perception of self-motion (heading) in abstinent ecstasy and marijuana users.

Authors:  M Rizzo; C T J Lamers; C G Sauer; J G Ramaekers; A Bechara; G J Andersen
Journal:  Psychopharmacology (Berl)       Date:  2005-02-19       Impact factor: 4.530

5.  Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model.

Authors:  V Sandoval; E L Riddle; Y V Ugarte; G R Hanson; A E Fleckenstein
Journal:  J Neurosci       Date:  2001-02-15       Impact factor: 6.167

6.  The nature of ecstasy-group related deficits in associative learning.

Authors:  Catharine Montgomery; John E Fisk; Russell Newcombe
Journal:  Psychopharmacology (Berl)       Date:  2005-01-25       Impact factor: 4.530

7.  Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.

Authors:  Onica Legendre; Stevan Pecic; Sandeep Chaudhary; Sarah M Zimmerman; William E Fantegrossi; Wayne W Harding
Journal:  Bioorg Med Chem Lett       Date:  2009-11-20       Impact factor: 2.823

Review 8.  3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings.

Authors:  Michael H Baumann; Xiaoying Wang; Richard B Rothman
Journal:  Psychopharmacology (Berl)       Date:  2006-03-16       Impact factor: 4.530

9.  Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA).

Authors:  Michael H Baumann; Richard B Rothman
Journal:  Int Rev Neurobiol       Date:  2009       Impact factor: 3.230

Review 10.  The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders.

Authors:  Maddalena Mereu; Antonello Bonci; Amy Hauck Newman; Gianluigi Tanda
Journal:  Psychopharmacology (Berl)       Date:  2013-08-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.